Loading...
•
Mar 31, 2021
Matinas BioPharma Q1 2021 Earnings Report
Matinas BioPharma reported financial results for the first quarter ended March 31, 2021, along with a corporate update.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $5.2 million, or a net loss of $0.03 per share for the first quarter of 2021. Cash, cash equivalents and marketable securities were approximately $60.7 million at March 31, 2021.
Enrollment continues in second cohort of EnACT study of MAT2203 in cryptococcal meningitis; DSMB evaluation anticipated Q3 2021.
MAT2501 advanced into preclinical toxicology and efficacy studies; completion of Phase 1 SAD study anticipated by end of 2021.
Matinas to host virtual R&D Day on June 17, 2021 to highlight LNC platform and related programs.
Data from ENHANCE-IT study of LYPDISO™ against Vascepa® support continued development of LYPDISO; partnership process ongoing.